PARTICIPANT ID | METHODOLOGY |
---|---|
Consultant Haematologist 1 | Focus groups |
Consultant Haematologist 2 | |
Advanced Nurse Practitioner 1 | |
Advanced Nurse Practitioner 2 | |
Advanced Nurse Practitioner 3 | |
Patient 1 | |
Patient 2 | |
Patient 3 | |
Patient 5 | |
Patient 6 | |
Consultant Haematologist 3 | 1:1 qualitative interviews |
Consultant Haematologist 4 | |
Consultant Haematologist 5 | |
Consultant Haematologist 6 | |
Consultant Haematologist 7 | |
Patient 4 | |
Patient 7 |
PARTICIPANT GROUP | CONSULTANT HAEMATOLOGISTS (N=7) | ADVANCED NURSE PRACTITIONERS (N=3) | PATIENTS (N=7) |
---|---|---|---|
50 | 18 | 30 | |
13 | 8 | 11 | |
Bias Clinician influence Clinician risk-training Clinician gateway for the NHS Cost containment Gene therapy Importance of MDT Media influence Nature of haemophilia as a disease Patient communication Risk Structure of consultations Uncertainty |
Benefit-risk Bias Gene therapy Inequity of focus Importance of MDT Timing of consultation Training Treatment choices |
Active vs. passive patients Consultation structure Evidence sources for new treatments Experience with current treatment and care Gateway for the NHS Gene therapy Geographical differences in care Health literacy Impact of blood inquiry Importance of MDT Treatment choices |
|
Active vs. passive patients Health literacy Gene therapy perspectives External factors Scar of blood infection scandal |